Fibrocell Science, Inc., (Nasdaq: FCSC) 18% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell’s lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.
Orexigen Therapeutics (NASDAQ: OREX) 14.8% LOWER; Orexigen and Takeda are in arbitration on terms of collaboration, the company’s CEO says in Bank of America presentation, according to CNBC’s